CAMBRIDGE, Mass., May 18, 2016 /PRNewswire/ -- Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stem cell (CSC) pathways, will feature clinical data on investigational compounds napabucasin (BBI-608) and amcasertib (BBI-503) in multiple tumor types at the 2016 American Society of Clinical Oncology annual meeting, held from June 3 to June 7, in Chicago.
Data to be exhibited underscore the potential of napabucasin – an orally administered investigational cancer stemness inhibitor designed to inhibit CSC pathways by targeting STAT3 – to enhance anti-cancer activity when used in combination with other chemotherapeutics.i Data will be shared across multiple tumor types, including the company's first results in ovarian, lung and breast cancers. Updated data in colorectal and pancreatic cancers from ongoing phase Ib extension studies will also be provided.
Also the first data in head and neck cancer from an ongoing phase I extension study of amcasertib – an orally administered investigational agent designed to inhibit cancer stem cell pathways, including Nanog, by targeting stemness kinases – will be shared at the meeting, both in poster format as well as in a poster discussion session.
"Boston Biomedical is pleased to share new clinical data on first-in-class cancer stemness inhibitors napabucasin and amcasertib at this year's ASCO annual meeting," said Chiang J. Li, M.D. FACP, the President, CEO and Chief Medical Officer of Boston Biomedical, and the Head of Global Oncology for Sumitomo Dainippon Pharma Group. "These findings support the potential for napabucasin and amcasertib to address a broad range of tumor types, which ultimately could lead to a new approach in treating cancer through targeting CSC pathways"
Planned poster sessions include:
Saturday, June 4 from 8:00 a.m. – 11:30 a.m. [Gastrointestinal (Colorectal) Cancer], Hall A
- Abstract #3564, Poster #261: Phase Ib extension study of cancer stemness inhibitor BB608 (Napabucasin) administered in combination with FOLFIRI +/- Bevacizumab (Bev) in patients (pts) with advanced colorectal cancer (CRC)
- O'Neil BH1, Hubbard JM2, Starodub A3, Jonker D4, Edenfield WJ5, El-Rayes B6, Halfdanarson TR2, Ramanathan R7, Pitot H2, Britten C8, Grothey A2, Borodyansky L9 and Li CJ9
- 1. IU Health University Hospital, Indianapolis, IN; 2. Mayo Clinic, Rochester, MN; 3. IU Goshen Health Center; 4. The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; 5. Institute for Translational Oncology Research, Greenville, SC; 6. The Winship Cancer Institute of Emory University, Atlanta, GA; 7. Mayo Clinic, Scottsdale, AZ; 8. MUSC Hollings Cancer Center, Charleston, SC; 9. Boston Biomedical, Inc., Cambridge, MA
Saturday, June 4 from 8:00 a.m. – 11:30 a.m. [Gastrointestinal (Noncolorectal) Cancer], Hall A
- Abstract #4128, Poster #120: A Phase Ib extension study of cancer stemness inhibitor BB608 (Napabucasin) in combination with Gemcitabine and nab-Paclitaxel (nab-PTX) in patients (pts) with metastatic pancreatic cancer
- El-Rayes B1, Shahda S2, Starodub A3, O'Neil BH2, Hanna W4, Shaib W1, Oh C5, Li YZ5, Borodyansky L5, Li CJ5 and Bekaii-Saab T6
- 1. The Winship Cancer Institute of Emory University, Atlanta, GA; 2. IU Health University Hospital, Indianapolis, IN; 3. IU Health Goshen Center for Cancer Care, Goshen, IN; 4. University of Tennessee Medical Center, Knoxville, TN; 5. Boston Biomedical, Inc., Cambridge, MA; 6. The Ohio State University Wexler Medical Center, Columbus, OH.
Saturday, June 4 from 8:00 a.m. – 11:30 a.m. (Lung Cancer, Non-Small Cell Metastatic), Hall A
- Abstract #9093, Poster #416: A Phase Ib/II Study of Cancer Stemness Inhibitor Napabucasin (BB608) Combined with Weekly Paclitaxel in Advanced Non-Small Cell Lung Cancer
- Becerra C1, Spira A1, Conkling P1, Richey S1, Hanna W2, Cote G3, Heist R3, Langleben A4, Laurie S5, Edenfield WJ6, Kossler K7, Hume S7, Li Y7, Hitron M7, Li CJ7
- 1. US Oncology Research, TOPS Phase I Program, Woodlands, TX; 2. University of Tennessee Medical Center, Knoxville, TN; 3. Massachusetts General Hospital, Boston, MA; 4. St. Mary's Hospital, McGill University, Montreal, QC; 5. Ottawa Hospital Research Institute, Ottawa, ON; 6. Institute for Translational Oncology Research, Greenville Hospital System/University Medical Center, Greenville, SC; 7. Boston Biomedical, Inc., Cambridge, MA
Saturday, June 4 from 8:00 a.m. – 11:30 a.m. [Gastrointestinal (Noncolorectal) Cancer], Hall A
- Abstract #TPS4144, Poster #129b: The BRIGHTER trial: A phase III randomized double-blind study of BBI-608 + weekly paclitaxel versus placebo (PBO) + weekly paclitaxel in patients (pts) with pretreated advanced gastric and gastro-esophageal junction (GEJ) adenocarcinoma
- Shah MA1,8, Muro K2,8, Shitara K3,4,8, Tebbutt NC5,8, Bang YJ6,8, Lordick F7,8, Borodyansky L8,9, other BRIGHTER Investigators8 and Li CJ8,9
- 1. New York-Presbyterian Hospital Weill Cornell Medical School, New York, NY; 2. Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan; 3. Department of Gastroenterology GI Oncology Division, National Cancer Center Hospital East, Chiba, Japan; 4. Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Chiba, Japan; 5, Austin Health, Heidelberg, Victoria, Australia; 6. Seoul National University Hospital, Seoul, Republic of Korea; 7. University Cancer Center, University Hospital Leipzig, Leipzig, Germany; 8. Authorship was determined by the order of regional activation and patient enrollment; 9. Boston Biomedical, Inc., Cambridge, MA
Saturday, June 4 from 1:00 p.m. – 4:30 p.m. (Head and Neck Cancer), Hall A; Saturday, June 4 from 4:45 p.m. – 6:00 p.m. (Poster Discussion Session), S406
- Abstract #6018, Poster #340: Phase I Extension Clinical Study of BB503, a First-in-Class Cancer Stemness Kinase Inhibitor, in Adult Patients with Advanced Head and Neck Cancer
- Cote G1, Chau N2, Spira A3, Edenfield WJ4, Richards D3, Richey S3, Laurie S5, Wilks S3, Braiteh F3, Wang K6, Li Y6, Rogoff H6, Hitron M6, Li CJ6
- 1. Massachusetts General Hospital, Boston, MA; 2. Dana-Farber Cancer Institute, Boston, MA; 3. US Oncology Research, TOPS Phase I Program, Woodlands, TX; 4. Institute for Translational Oncology Research, Greenville Hospital System/University Medical Center, Greenville, SC; 5. Ottawa Hospital Research Institute, Ottawa, ON; 6. Boston Biomedical, Inc., Cambridge, MA
Sunday, June 5 from 8:00 a.m. – 11:30 a.m. (Breast Cancer, Triple Negative / Cytotoxics /Local Therapy), Hall A
- Abstract #1094, Poster #199: A Phase Ib/II Study of Cancer Stemness Inhibitor Napabucasin (BB608) Combined with Weekly Paclitaxel in Advanced Triple Negative Breast Cancer
- Becerra C1, Braiteh F1, Spira A1, Langleben A2, Panasci L2, Vukelja S1, Hinshaw I1, Goodwin R3, Panella T4, Edenfield WJ5, Kossler K6, Hume S6, Li Y6, Hitron MJ6, Li CJ6
- 1. US Oncology Research, TOPS Phase I Program, Woodlands, TX; 2. McGill University, Montreal, QC; 3. Ottawa Hospital Research Institute, Ottawa, ON; 4. University of Tennessee Medical Center, Knoxville, TN; 5. Institute for Translational Oncology Research, Greenville Hospital System/University Medical Center, Greenville, SC; 6. Boston Biomedical, Inc., Cambridge, MA
Monday, June 6 from 1:00 p.m. – 4:30 p.m. (Gynecologic Cancer), Hall A
- Abstract #5578, Poster #401: A Phase Ib/II Study of Cancer Stemness Inhibitor Napabucasin (BB608) Combined with Weekly Paclitaxel in Platinum Resistant Ovarian Cancer
- Garcia A1, Hays J2, Cote G3, Becerra C4, Langleben A5, Lau S5, Roman L1, McCormick C4, Richards D4, Braiteh F4, Yimer H4, Richey S4, Spira A4, Edenfield JW6, Kossler K7, Hume S7, Li Y7, Hitron MJ7, Li CJ7
- 1. University of Southern California, Los Angeles, CA; 2. The Ohio State University Comprehensive Cancer Center, Columbus, OH; 3. Massachusetts General Hospital, Boston, MA; 4. US Oncology Research, TOPS Phase I Program, Woodlands, TX; 5. McGill University, Montreal, QC; 6. Institute for Translational Oncology Research, Greenville Hospital System/University Medical Center, Greenville, SC; 7. Boston Biomedical, Inc., Cambridge, MA
About Boston Biomedical
Boston Biomedical, Inc. (Founder, President, CEO and CMO: Chiang J. Li, M.D. FACP) was founded in November 2006 and is wholly owned by Sumitomo Dainippon Pharma Co., Ltd. Boston Biomedical's mission is to develop the next generation of cancer therapeutics by creating drugs designed to target cancer stem cell pathways. Boston Biomedical's innovation in drug discovery has received a number of recognitions and awards in the United States, including the Frost & Sullivan 2010 North American Drug Discovery Technology Innovation of the Year Award, the National Cancer Institute (NCI) cancer stem cell initiative grant award in 2010, and the 2011 Biotech Pioneer Award at the Alexandria Oncology Summit. The company also received the "Company To Watch" award in the 10th Annual Team Massachusetts Economic Impact Awards in 2013. Boston Biomedical is headquartered in Cambridge, Massachusetts, USA.
Additional information about the company and its product pipeline can be found at www.bostonbiomedical.com.
Disclaimer Regarding Forward-Looking Statements
The forward-looking statements in this document are based on management's assumptions and beliefs in light of information presently available, and involve both known and unknown risks and uncertainties. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.
i Li Y, Rogoff HA, Keates, S, Gao Y, Murikipudi S, Mikule K, Leggett D, Wei L, Pardee A, Li CJ. Suppression of Cancer Relapse and Metastasis by Inhibiting Cancer Stemness. PNAS. 2015;112(6):1839-1844.
Logo - http://photos.prnewswire.com/prnh/20150514/216131LOGO
SOURCE Boston Biomedical Pharma, Inc.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article